Versiti Launches Beacon Biologics to Provide Custom Solutions to Researchers and Cell Therapy Developers Beacon Biologics to offer LeukoPaks® and unrivaled expertise in blood products News provided by Share this article Share this article AUSTIN, Texas, April 28, 2021 /PRNewswire/ -- Versiti, a national leader in blood health innovation, has launched Beacon Biologics to help provide custom solutions of high-quality, well-characterized biomaterials to researchers and cell therapy developers. Beacon Biologics leverages Versiti's depth of experience in donor recruitment, blood collection and apheresis procedures, as well as the logistics expertise of its multi-state blood network, to provide customized LeukoPaks®, blood products, and seamless support to those working to advance novel treatments for a variety of cancers, autoimmune disorders, and other rare diseases. The organization's IRB-approved registry database includes information such as high-resolution HLA typing, CMV status, and other donor selection criteria.